Skip to: Curated Story Group 1
lifesciencesreview

Advertise

with us

  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Topics
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Biomanufacturing
    Business Services
    Business Services
    Business Services
    Business Services
    Business Services
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Drug Discovery
    Pharmacy Management
    Regulatory Services
  • CXO Insights
  • Vendor Viewpoint
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • CXO Awards
NOVEMBER 2023LIFE SCIENCES REVIEW9particularly important when you have something novel to discuss. You will have multiple opportunities to educate regulators throughout the development and licensing process, but it is best to begin your regulatory collaboration early, before data submission or before they are generated.3. Create ClarityAlways remember that you are the expert on your technology or product, not the regulators. Many regulatory professionals mistakenly believe that questions from authorities come from a position of wisdom and greater knowledge. They incorrectly assume that regulators clearly understand everything they are presented with, so questions from them must be a critique.It is likely that regulator questions come simply from insufficient understanding and a lack of clarity regarding the information presented. Sometimes, the issue is one of terminology, as an entirely new technology improperly explained offers false or insufficient understanding for regulators. The best regulatory professionals can clearly explain their product and its benefits in language that regulators understand and can point regulators to the data supporting their arguments.Seeking SuccessRegulatory professionals are the essential link connecting product development and compliance, ensuring both are synchronised throughout an often lengthy process. By ensuring solid communication with regulators and remaining committed to patients' best interests, there is an opportunity to smooth the pathway. While the process can be complex, your new product will benefit the world, so every effort you make to approve it is worthwhile. One of the biggest challenges of this on-going innovation for the regulatory professional is how to guide organizations to effectively develop their newest complex drug product so it can be approved for use
< Page 8 | Page 10 >